Blake M Warner1, Bruce C Casto2, Thomas J Knobloch2, Brent T Accurso3, Christopher M Weghorst2. 1. University College of Public Health, The Ohio State University, Columbus, OH, USA; College of Dentistry The Ohio State University, Columbus, OH, USA; School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: warnerbm@upmc.edu. 2. University College of Public Health, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. 3. College of Dentistry The Ohio State University, Columbus, OH, USA.
Abstract
OBJECTIVE: To evaluate the preclinical efficacy of topical administration of freeze-dried black raspberries (BRBs) to inhibit the progression of premalignant oral lesions and modulate biomarkers of cancer development in high at-risk mucosa (HARM). STUDY DESIGN: Hamster cheek pouches (HCPs) were treated with carcinogen for 6 weeks to initiate a HARM microenvironment. Subsequently, right HCPs were topically administered a BRB suspension in short-term or long-term studies. After 12 weeks, squamous cell carcinoma (SCC) multiplicity, SCC incidence, and cell proliferation rates were evaluated. mRNA expression was measured in short-term treated pouches for selected oral cancer biomarkers. RESULTS: SCC multiplicity (-41.3%), tumor incidence (-37.1%), and proliferation rate (-6.9%) were reduced in HCPs receiving BRBs. Topical BRBs correlated with an increase in RB1 expression in developing oral lesions. CONCLUSIONS: Topical BRBs inhibit SCC development when targeted to HARM tissues. These results support the translational role of BRBs to prevent oral cancer development in humans.
OBJECTIVE: To evaluate the preclinical efficacy of topical administration of freeze-dried black raspberries (BRBs) to inhibit the progression of premalignant oral lesions and modulate biomarkers of cancer development in high at-risk mucosa (HARM). STUDY DESIGN:Hamster cheek pouches (HCPs) were treated with carcinogen for 6 weeks to initiate a HARM microenvironment. Subsequently, right HCPs were topically administered a BRB suspension in short-term or long-term studies. After 12 weeks, squamous cell carcinoma (SCC) multiplicity, SCC incidence, and cell proliferation rates were evaluated. mRNA expression was measured in short-term treated pouches for selected oral cancer biomarkers. RESULTS:SCC multiplicity (-41.3%), tumor incidence (-37.1%), and proliferation rate (-6.9%) were reduced in HCPs receiving BRBs. Topical BRBs correlated with an increase in RB1 expression in developing oral lesions. CONCLUSIONS: Topical BRBs inhibit SCC development when targeted to HARM tissues. These results support the translational role of BRBs to prevent oral cancer development in humans.
Authors: Stephen A Bustin; Vladimir Benes; Jeremy A Garson; Jan Hellemans; Jim Huggett; Mikael Kubista; Reinhold Mueller; Tania Nolan; Michael W Pfaffl; Gregory L Shipley; Jo Vandesompele; Carl T Wittwer Journal: Clin Chem Date: 2009-02-26 Impact factor: 8.327
Authors: L A Kresty; M A Morse; C Morgan; P S Carlton; J Lu; A Gupta; M Blackwood; G D Stoner Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701
Authors: Nancy N Zikri; Kenneth M Riedl; Li-Shu Wang; John Lechner; Steven J Schwartz; Gary D Stoner Journal: Nutr Cancer Date: 2009 Impact factor: 2.900
Authors: G K Harris; A Gupta; R G Nines; L A Kresty; S G Habib; W L Frankel; K LaPerle; D D Gallaher; S J Schwartz; G D Stoner Journal: Nutr Cancer Date: 2001 Impact factor: 2.900
Authors: Gary D Stoner; Alan A Dombkowski; Rashmeet K Reen; Daniela Cukovic; Sridevi Salagrama; Li-Shu Wang; John F Lechner Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Bruce C Casto; Laura A Kresty; Carrie L Kraly; Dennis K Pearl; Thomas J Knobloch; Herman A Schut; Gary D Stoner; Susan R Mallery; Christopher M Weghorst Journal: Anticancer Res Date: 2002 Nov-Dec Impact factor: 2.480
Authors: F J Duncan; Jason R Martin; Brian C Wulff; Gary D Stoner; Kathleen L Tober; Tatiana M Oberyszyn; Donna F Kusewitt; Anne M Van Buskirk Journal: Cancer Prev Res (Phila) Date: 2009-07
Authors: Steve Oghumu; Thomas J Knobloch; Cesar Terrazas; Sanjay Varikuti; Jennifer Ahn-Jarvis; Claire E Bollinger; Hans Iwenofu; Christopher M Weghorst; Abhay R Satoskar Journal: Int J Cancer Date: 2016-06-16 Impact factor: 7.396
Authors: Matthew D Teegarden; Thomas J Knobloch; Christopher M Weghorst; Jessica L Cooperstone; Devin G Peterson Journal: Food Funct Date: 2018-09-19 Impact factor: 5.396
Authors: Steve Oghumu; Bruce C Casto; Jennifer Ahn-Jarvis; Logan C Weghorst; Jim Maloney; Paul Geuy; Kyle Z Horvath; Claire E Bollinger; Blake M Warner; Kurt F Summersgill; Christopher M Weghorst; Thomas J Knobloch Journal: Front Immunol Date: 2017-10-23 Impact factor: 7.561